A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

The ELI-002 2P vaccine uses peptides to train the immune system to spot and destroy cells with KRAS mutations.

According to them, the vaccine can safely and effectively train the immune system to recognise and fight cancer-driving ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back.

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...